Nephros (NASDAQ:NEPH) Shares Down 2.8% – Here’s Why

Nephros, Inc. (NASDAQ:NEPHGet Free Report) was down 2.8% during mid-day trading on Monday . The stock traded as low as $1.60 and last traded at $1.60. Approximately 5,861 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 7,553 shares. The stock had previously closed at $1.65.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “speculative buy” rating and issued a $5.00 target price on shares of Nephros in a report on Tuesday, November 12th.

Read Our Latest Stock Analysis on Nephros

Nephros Stock Down 2.8 %

The company’s fifty day moving average is $1.55 and its two-hundred day moving average is $1.72. The stock has a market cap of $16.86 million, a price-to-earnings ratio of -17.78 and a beta of 1.19.

Institutional Investors Weigh In On Nephros

A hedge fund recently bought a new stake in Nephros stock. Dimensional Fund Advisors LP acquired a new position in shares of Nephros, Inc. (NASDAQ:NEPHFree Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned approximately 0.17% of Nephros as of its most recent filing with the SEC. Hedge funds and other institutional investors own 41.10% of the company’s stock.

Nephros Company Profile

(Get Free Report)

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Read More

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.